Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 October 2014Website:
http://www.atarabio.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 19:51:14 GMTDividend
Analysts recommendations
Institutional Ownership
ATRA Latest News
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Virtual Cell Therapy Forum on Tuesday, July 9, 2024 at 6:45 a.m. PDT / 9:45 a.m. EDT. A live web.
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that EbvalloTM (tabelecleucel or tab-cel®) has been awarded the prestigious 2024 Prix Galien International Award for “Best Product for Orphan/Rare Diseases.” The award was presented to Pierre Fabre Laborato.
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Atara has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (tab-cel®) indicated as monotherapy for treatment of adult and pediatric patie.
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.72 per share a year ago.
Atara Biotherapeutics is a biotech company focused on developing cell therapies for Epstein-Barr virus infection and cancer. Their most advanced product, tab-cel, has shown promising results in treating EBV-associated post-transplant lymphoproliferative disease. The company's financial situation is uncertain, but recent partnerships and potential revenue growth from tab-cel could improve their cash runway.
Penny stocks offer investors the chance to get in on the ground floor of small companies with growth potential. They also offer high-volatility trading opportunities daily that can see huge moves of 100% or more.
Penny stocks are often priced under $5 per share. They attract traders seeking big gains.
Atara Biotherapeutics stock price dropped by 80% following failure of ATA188 in a phase 2 study in multiple sclerosis. This was an excessive reaction by the market in my opinion. ATRA's restructuring, tab-cel deal with Pierre Fabre, and lower future R&D expenses (considering failure of ATA188 and prioritization of ATA3219 and ATA3431) have extended cash runaway beyond Q3 2025. Pierre Fabre will not only take over all costs associated with tab-cel but will also pay ATRA $30M upfront, as well as $100M in regulatory milestone payments through BLA approval.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA ) Q3 2023 Results Conference Call November 1, 2023 9:00 AM ET Company Participants Alex Chapman - VP, Corporate Communications & IR Dr. Pascal Touchon - President and CEO Eric Hyllengren - CFO Conference Call Participants Salim Syed - Mizuho John Newman - Canaccord Genuity Phil Nadeau - Cowen & Company Jonathan Miller - Evercore ISI Tommie Reerink - Goldman Sachs Operator Good morning, and thank you for standing by. Welcome to Atara Biotherapeutics' Third Quarter 2023 Financial Results Conference Call.
Atara (ATRA) rises 11% on an update regarding the regulatory pathway for the company's lead product candidate, tab-cel, in the treatment of a rare, deadly and hematologic malignancy.
What type of business is Atara Biotherapeutics?
Atara Biotherapeutics, Inc. is a biotechnology company that is developing new methods of treating patients with cancer, autoimmune, and viral diseases. The company specializes in allogeneic T-cell immunotherapy. It was founded in 2012 and is headquartered in San Francisco, California. The company's priority programs/strategies are: - Tab-cel: an advanced T-cell immunotherapy in Phase 3 clinical development, designed for patients with Epstein-Barr virus. - ATA188: T-cell immunotherapy targeting EBV antigens, considered important for potential treatment of multiple sclerosis. - ATA2271/ATA3271: immunotherapy for patients with hematologic malignancies, solid tumors, and viral diseases. - ATA3219: immunotherapy aimed at treating patients with B-cell lymphomas.
What sector is Atara Biotherapeutics in?
Atara Biotherapeutics is in the Healthcare sector
What industry is Atara Biotherapeutics in?
Atara Biotherapeutics is in the Biotechnology industry
What country is Atara Biotherapeutics from?
Atara Biotherapeutics is headquartered in United States
When did Atara Biotherapeutics go public?
Atara Biotherapeutics initial public offering (IPO) was on 16 October 2014
What is Atara Biotherapeutics website?
https://www.atarabio.com
Is Atara Biotherapeutics in the S&P 500?
No, Atara Biotherapeutics is not included in the S&P 500 index
Is Atara Biotherapeutics in the NASDAQ 100?
No, Atara Biotherapeutics is not included in the NASDAQ 100 index
Is Atara Biotherapeutics in the Dow Jones?
No, Atara Biotherapeutics is not included in the Dow Jones index
When does Atara Biotherapeutics report earnings?
The next expected earnings date for Atara Biotherapeutics is 08 August 2024